Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
MeiraGTx Holdings plc - Ordinary Shares
(NQ:
MGTX
)
11.84
+0.36 (+3.14%)
Streaming Delayed Price
Updated: 10:06 AM EDT, Jun 23, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
86,216
Open
11.35
Bid (Size)
11.82 (200)
Ask (Size)
11.86 (100)
Prev. Close
11.48
Today's Range
11.28 - 11.85
52wk Range
6.070 - 11.85
Shares Outstanding
80,479,684
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 14, 2026
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Reports First Quarter 2026 Financial and Operational Results
May 14, 2026
From
MeiraGTx
Via
GlobeNewswire
Performance
YTD
+51.6%
+51.6%
1 Month
+23.3%
+23.3%
3 Month
+54.8%
+54.8%
6 Month
+42.7%
+42.7%
1 Year
+87.6%
+87.6%
More News
Read More
MeiraGTx Holdings (NASDAQ:MGTX) Passes Minervini Trend Template and High Growth Momentum Screen
↗
May 14, 2026
Via
Chartmill
MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares
April 16, 2026
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)
April 16, 2026
From
MeiraGTx
Via
GlobeNewswire
MGTX Stock Soared 13% Today – What’s The Eli Lilly Angle?
↗
November 10, 2025
Via
Stocktwits
MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia
April 16, 2026
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026
April 14, 2026
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results
March 26, 2026
From
MeiraGTx
Via
GlobeNewswire
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
February 17, 2026
Via
Investor Brand Network
Topics
Intellectual Property
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
February 17, 2026
From
BioMedWire
Via
GlobeNewswire
The Biotech Tug-of-War: Is Kiora Pharmaceuticals Positioned to Ride the 2025 Commodity Wave?
December 18, 2025
Via
MarketMinute
Topics
Derivatives
Economy
Intellectual Property
MeiraGTx Reports Third Quarter 2025 Financial and Operational Results
November 13, 2025
From
MeiraGTx
Via
GlobeNewswire
Eli Lilly Expands Genetic Eye-Disease Focused Pipeline With MeiraGTx Gene Therapy Collaboration
↗
November 10, 2025
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
November 10, 2025
Via
Benzinga
MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology
November 10, 2025
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress
October 07, 2025
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Sales Jump 1,133 Percent
↗
August 14, 2025
Via
The Motley Fool
MeiraGTx Reports Second Quarter 2025 Financial and Operational Results
August 14, 2025
From
MeiraGTx
Via
GlobeNewswire
Coinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday
↗
May 14, 2025
Via
Benzinga
MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting
May 13, 2025
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Reports First Quarter 2025 Financial and Operational Results
May 13, 2025
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease
May 09, 2025
From
MeiraGTx
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
March 13, 2025
Via
Benzinga
There are notable gap-ups and gap-downs in today's session.
↗
March 13, 2025
Via
Chartmill
Frequently Asked Questions
Is MeiraGTx Holdings plc - Ordinary Shares publicly traded?
Yes, MeiraGTx Holdings plc - Ordinary Shares is publicly traded.
What exchange does MeiraGTx Holdings plc - Ordinary Shares trade on?
MeiraGTx Holdings plc - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for MeiraGTx Holdings plc - Ordinary Shares?
The ticker symbol for MeiraGTx Holdings plc - Ordinary Shares is MGTX on the Nasdaq Stock Market
What is the current price of MeiraGTx Holdings plc - Ordinary Shares?
The current price of MeiraGTx Holdings plc - Ordinary Shares is 11.84
When was MeiraGTx Holdings plc - Ordinary Shares last traded?
The last trade of MeiraGTx Holdings plc - Ordinary Shares was at 06/23/26 10:06 AM ET
What is the market capitalization of MeiraGTx Holdings plc - Ordinary Shares?
The market capitalization of MeiraGTx Holdings plc - Ordinary Shares is 952.88M
How many shares of MeiraGTx Holdings plc - Ordinary Shares are outstanding?
MeiraGTx Holdings plc - Ordinary Shares has 953M shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
